---
title: "Replimune FY27 Q1 net loss narrows to $69.8 million; R&D expenses fall to $49.3 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295931365.md"
description: "Replimune reported a narrowed GAAP net loss of $69.8 million for FY27 Q1, down from $86.7 million prior year. R&D expenses decreased to $49.3 million, and SG&A costs dropped to $19 million. The company ended the quarter with $195.3 million in cash and investments, bolstered by a recent equity issuance. Additionally, the FDA granted accelerated approval for TUDRIQEV with nivolumab for advanced melanoma."
datetime: "2026-08-14T12:02:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295931365.md)
  - [en](https://longbridge.com/en/news/295931365.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295931365.md)
generator: "portal-rs"
---

# Replimune FY27 Q1 net loss narrows to $69.8 million; R&D expenses fall to $49.3 million

-   Replimune posted a GAAP net loss of USD 69.8 million for fiscal Q1 ended June 30, 2026, narrowing from USD 86.7 million a year earlier. \* R&D expense fell to USD 49.3 million from USD 57.8 million, on lower personnel and direct research costs across IGNYTE, ARTACUS, CERPASS. \* Selling, general and administrative costs dropped to USD 19 million from USD 32.6 million, including USD 4.1 million of stock-based compensation. \* Cash, cash equivalents and short-term investments totaled USD 195.3 million at quarter-end; August equity issuance added USD 141 million net proceeds. \* FDA granted accelerated approval to TUDRIQEV with nivolumab in advanced melanoma; U.S. launch expected within 60 days, IGNYTE-3 readout targeted 2030. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140800PRIMZONEFULLFEED9810154) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)

## Related News & Research

- [17:00 ETReplimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit](https://longbridge.com/en/news/296955124.md)
- [04:15 ETReplimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL](https://longbridge.com/en/news/297146499.md)
- [Lytix says FDA clears Phase III trial plan for ruxotemitide plus pembrolizumab in high-risk melanoma](https://longbridge.com/en/news/297124839.md)
- [Lytix Biopharma partners on Phase II ALETTA trial of ruxotemitide with ipilimumab, nivolumab in resectable melanoma](https://longbridge.com/en/news/297066836.md)
- [Biovica says DiviTum TKa study in metastatic melanoma is published in Clinical Cancer Research](https://longbridge.com/en/news/296871354.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**